Amarin Downplayed Threat Of Vascepa Fight, Investor Says
An Amarin shareholder launched a derivative action Thursday in New Jersey federal court alleging company officials downplayed the risk of litigation that ultimately left certain patents for its heart drug Vascepa...To view the full article, register now.
Already a subscriber? Click here to view full article